Related Experiment Video
Updated: Jul 11, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Acute pancreatitis associated with sorafenib
1Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, USA.
Abstract:
Since its FDA approval in December 2005, sorafenib (Nexavar) has been in use for the treatment of metastatic renal cell carcinoma. With this increased use have come reports of adverse effects of sorafenib. To the best of the authors' knowledge, they are the first to describe an 80-year-old Asian male with a history of metastatic renal cell carcinoma who developed acute pancreatitis confirmed by computed tomography (CT) one month after taking sorafenib 400 mg orally twice a day. Sorafenib was eventually discontinued, and the pancreatitis resolved. The molecular biologic mechanism causing this side effect is discussed. Patients should be informed of this rare but potentially serious adverse effect before initiation of sorafenib therapy. Early recognition of this complication and complete discontinuation of sorafenib are recommended.
Insights
Sorafenib, used for metastatic renal cell carcinoma, can cause acute pancreatitis. This rare side effect resolved after discontinuing the drug, highlighting the need for patient awareness and early detection.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Background:
- Sorafenib (Nexavar) is an FDA-approved tyrosine kinase inhibitor for metastatic renal cell carcinoma (mRCC).
- Increased use of sorafenib has led to reports of various adverse effects.
- Renal cell carcinoma is a significant malignancy requiring effective treatment options.
Observation:
- A case report details an 80-year-old Asian male with mRCC who developed acute pancreatitis.
- The pancreatitis was confirmed via computed tomography (CT) scan.
- Symptoms emerged one month after initiating sorafenib 400 mg twice daily.
Findings:
- The patient's acute pancreatitis resolved after sorafenib discontinuation.
- This represents a rare but potentially serious adverse effect of sorafenib therapy.
- The molecular mechanisms underlying sorafenib-induced pancreatitis are discussed.
Implications:
- Patients should be informed about the risk of acute pancreatitis before starting sorafenib.
- Early recognition and prompt cessation of sorafenib are crucial for managing this complication.
- This case underscores the importance of monitoring for gastrointestinal adverse events in patients receiving targeted cancer therapies.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis II: Pathophysiology
Acute Pancreatitis I: Introduction
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...